MedTrace Logo

Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin

NCT05089357 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2025-07-09

Study results available
· View outcomes & findings →

Summary

This is a prospective, longitudinal, non-interventional, multi-center study to collect subject and physician satisfaction, and treatment experience with Dysport in real clinical practice in subjects of Chinese origin.

Conditions

  • Glabellar Lines

Interventions

BIOLOGICAL

AbobotulinumtoxinA

Participants received a total dose of AbobotulinumtoxinA (Dysport®), 50 U (0.25 mL total; 10 U \[0.05 mL per injection site\] of study drug into 5 injection sites intramuscularly.

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Weiming Song · Hangzhou Yanshuyuerong medical cosmetology clinic

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-11
Primary Completion
2023-09-12
Completion
2023-12-24

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05089357 on ClinicalTrials.gov